RD Biomed and the Peptest team headed to the Czech Republic’s largest pulmonary disease conference in Pilsen in early November.
The three-day IV. Kongres České pneumologické a ftizeologické společnosti ČLS Plzen included parallel speaker sessions, poster presentations and a trade exhibition across pneumology and respiratory issues.
Professor Peter Dettmar presented Peptest and its significance in diagnosing reflux disease at the conference. It is estimated that airway reflux/ laryngopharyngeal reflux (LPR) affects 20 to 40 per cent of western population.
Pepsin is present in all refluxate in contrast to other gastric components, such as acid or bile acids. It is also considered as a sensitive and specific biomarker for LPR and respiratory disease.
At the conference, Peter and RD Biomed’s laboratory manager Andrew Woodcock also met up with the Imedex s.r.o team – our exclusive distributor in the Czech Republic – and industry colleagues, including Professor Milos Pesek.
Peptest detects pepsin — the stomach enzyme that indicates reflux — in a saliva sample. Developed by the late Professor Peter Dettmar and used in over 40 countries, it is available directly to patients as well as NHS and private clinics.
- CE-IVD certified
- ISO 13485 manufacture
- Validated in 1,033-patient UK study
- Used in NHS voice clinics
Recent Comments